Join us on Wall Street StreetInsider Premium. Request your 1-week free trial here.
Industry-leading nerve repair surgeons will discuss data-driven best practices during the symposium session
ALACHUA & TAMPA, Fla., Sept. 22, 2022 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in the development and commercialization of innovative surgical solutions for peripheral nerve damage or disruptions, has announced its participation at the 77thth American Society for Surgery of the Hand (ASSH) Annual Meeting September 29-October 1, 2022 in Boston.
During the conference, Axogen will host an industry forum symposium on Friday, September 30 from 7:00 a.m. to 8:00 a.m. entitled Late-Breaking, State-of-the-Art Nerve Reconstruction Data: The How and Why of Implementing this New Data into Your Host Clinical Practice :00 p.m. ET. This session will include interactive Q&A with surgical investigators who will present the results of a newly completed randomized controlled trial on nerve repair, as well as a new comprehensive meta-analysis on peripheral nerve repair that reports results for autograft and allograft both sensory and mixed/motor nerve repairs are compared.
Attending surgeons will have the opportunity to meet Axogen staff, clinicians and other experts at booth #815 in the Solutions Center (Exhibit Hall) and participate in hands-on demonstrations. Fully equipped microscope stations will encourage surgeons to learn more about microsurgical techniques, product handling and other innovative surgical solutions for peripheral nerve repair. In addition to the interactive capabilities at the booth, surgeons will be invited to meet Axogen’s top scientists in an innovation lab to delve deeper into how science is improving nerve repair.
In addition to the symposium, Axogen will support the Young Surgeons Skills Bootcamp and Women in Hand Surgery, and will sponsor two travel grants for Residents or Fellows to attend the Boston convention.
“We look forward to meeting and connecting with hand surgeons during our symposium and booth,” said Karen Zaderej, Axogen Chair, CEO and President. “The annual ASSH conference is a valuable event to drive innovation and an important forum for Axogen’s growing portfolio of clinical data as we continue to pursue our mission of improving the lives of patients with peripheral nerve damage.”
Axogen is proud to support various ASSH research, education and outreach programs throughout the year, including the ASSH Touching Hands International Missions. These missions provide life-changing hand surgery, rehabilitation and medical education in the world’s most underserved communities.
The American Society for Surgery of the Hand is the oldest medical society dedicated to the hand and upper extremity. Its mission is to advance the science and practice of hand and upper extremity surgery through education, research, and advocacy on behalf of patients and physicians. Visit www.assh.org for more information.
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about restoring the function and quality of life of patients with physical damage or peripheral nerve transections by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that affect the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to reconnect peripheral nerves properly can result in loss of muscle or organ function, loss of sensory sensation, or induction of pain.
The Axogen platform for peripheral nerve repair includes a comprehensive product portfolio, including Avance® Nerve Graft, a biologically active, commercially available, processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard nerve connector®a submucosal porcine extracellular matrix (ECM) adaptation aid for the tension-free repair of severed peripheral nerves; Axoguard nerve protection®, a porcine submucosal ECM device used to envelop and protect damaged peripheral nerves and enhance nerve reconstruction while preventing soft tissue attachments; and Axoguard nerve cap®, a porcine submucosal ECM product used to protect a peripheral nerve ending and isolate the nerve from the environment to reduce the development of a symptomatic or painful neuroma. Axogen’s product portfolio is available in the US, Canada, Germany, UK, Spain, South Korea and several other countries.
Ed Joyce, Director, Investor Relations